In stroke patients subjected to pharmacological recanalization with recombinant tissue plasminogen activator (rtPA), TT-genotype variant of both MMP-9 -1562C/T polymorphism and of its inhibitory counterpart TIMP-2 -303C/T was related with significantly increased risk of hemorrhagic stroke transformation [169]. This evidence concerns the gene MMP9 and hemorrhagic stroke.